DSwiss, Inc. reported a net loss of $76,860 for the year ended December 31, 2025, a reversal from a net profit of $22,223 in 2024. Revenue decreased by 6.16% to $2,920,986 in 2025 from $3,112,887 in 2024. Gross profit fell to $564,562 in 2025 from $623,271 in 2024, with gross margin decreasing from 20.02% to 19.33%. The company experienced negative cash flow from operating activities of $94,303 in 2025, compared to generating $182,556 in 2024. A working capital deficit of $133,691 was reported as of December 31, 2025, a deterioration from a surplus of $13,645 in 2024. Accumulated deficit increased to $1,464,790 in 2025 from $1,387,930 in 2024. Management identified material weaknesses in internal control over financial reporting, including a lack of written policies and procedures and inadequate segregation of duties. The company operates as a biotech nutraceutical firm and OEM/ODM provider of health and beauty products, with operations primarily in Malaysia and Hong Kong, and a presence across the Asia-Pacific region.